Milestone: First TCR-T Therapy Files for Approval
- Moderna Latest Study: mRNA Therapy for Treating T Cell-Mediated Autoimmune Diseases
- The Biosecure Act May Hurt Pharmaceutical Supply Chains
- Mosquito Elimination on Global Health: Unraveling the Claim of 700K Annual Deaths
- Intensive Blood Pressure Management to Below 140 mmHg Reduces Stroke Risk, Regardless of Medication Dosage
- GLP-1 Drugs: How Significant is Their Impact on Brain Health?
- Why Eel Sashimi Is Unsafe: Understanding the Risks of Consuming Raw Eel
Milestone: First TCR-T Therapy Files for Approval
- Shocking! All existing AIDS vaccine developments have failed
- Sanofi Japan Data Breach: 730000 Healthcare Professionals’ Information Exposed
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Milestone: First TCR-T Therapy Files for Approval
On January 31, 2024, Adaptimmune announced that the market application for their TCR-T therapy, Afami-cel, has been accepted by the FDA and granted priority review status, with a PDUFA date set for August 4 of this year.
Afami-cel marks Adaptimmune’s inaugural pipeline, targeting MAGE-A4, designed for the treatment of a type of soft tissue tumor known as synovial sarcoma.
This therapy holds the potential to be the first T-cell therapy for solid tumors, making it a groundbreaking achievement if successfully approved.
Synovial sarcoma, a subtype of soft tissue tumors, accounts for approximately 5-10% of the 13,000 new cases of soft tissue tumors diagnosed annually in the United States. The five-year survival rate for synovial sarcoma is merely 20%, highlighting a significant unmet clinical need.
Adaptimmune anticipates a peak sales value of $400 million for the combined Afami-cel and lete-cel therapies.
Afami-cel has demonstrated a 39% Objective Response Rate (ORR) in later-line treatments.
With a two-year survival rate of 70%, Afami-cel’s median Overall Survival (mOS) is estimated at 17 months, surpassing historical data with a comparison of less than 12 months.
In summary, the success of Afami-cel is a milestone, indicating a shift in cancer treatment targets from membrane/extracellular to intracellular domains, opening up new possibilities in target selection.
The approval of Afami-cel is eagerly awaited, offering improved treatment options for synovial sarcoma patients.
Milestone: First TCR-T Therapy Files for Approval
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
